Suzetrigine in the Management of Pain Review of the First-in-class Na V1.8 Selective Inhibitor
Artículo
Acceso abierto
Artículo
DOAJ
Introduction. The 2025 FDA approval of suzetrigine (Journavx) ended a 25-year stagnation in analgesic development. This introduced a paradigm shift in pain management. As a first-in-class, highly selective NaV1.8 sodium...
LCC TENDOkVkdWNhdGlvbg~~; TENDOlNwb3J0cw~~; LCC:MedicineIdioma eng
Acceso abiertoRuta libre sin proxy. Acceso recomendado cuando no hay suscripción activa.
Open Access